25+ results for “Capsid immunogenicity”
Human IgG Fc promotes expression, secretion and immunogenicity of enterovirus 71 VP1 protein
Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types
A systematic capsid evolution approach performed in vivo for the design of AAV vectors with tailored properties and tropism
Artificial intelligence and the transformation of cell and gene therapy development
Chimeric serotype combining AAV2 and AAV5 capsid sequences for enhanced muscle transduction with improved tissue distribution.
Muscle-tropic AAV capsid from M-CREATE directed evolution with high skeletal and cardiac muscle transduction efficiency and a distinct biodistribution profile from MyoAAV-1A. Cross-species validated in mouse, pig, and non-human primate, enabling capsid selection tailored to specific disease indications. Alternative or comparator to MyoAAV-1A for muscular dystrophy and cardiomyopathy gene therapy.
First successful chimeric AAV created through DNA family shuffling of AAV2, AAV8, and AAV9. Proof-of-concept for rational capsid engineering and hybrid vector design.
Naturally occurring AAV6 variant with distinct capsid sequence and improved transduction characteristics in muscle and liver.